Poly-targeting Therapies to Transform Treatment of Complex Diseases
Immune disorders frequently involve multiple dysregulated pathways, making them poorly suited to traditional mono-targeting therapies such as small molecules, antibodies, and siRNA. Because of this, many of these diseases have treatments with limited efficacy or no approved treatments at all.
Who We Are
Polyrna Therapeutics is a pre-clinical biotech startup with a platform technology to rationally design novel poly-targeting RNAi.
We apply the latest RNAi, bioinformatics, and scientific research to transform treatment options for the millions of patients suffering from immunoregulatory disorders.
Our founding team has a strong interdisciplinary background in biology, data science, and high-performance software development that's allowed us to bring our technology to life.
What We Do
At Polyrna Therapeutics we understand that many immune diseases are complex and not caused by just a single protein or pathway. To enable better treatments for these diseases, we've developed a proprietary bioinformatic platform platform that designs novel poly-targeting microRNA (miRNA) able to simultaneously regulate multiple disease-causing proteins while minimizing off-target interactions.
We design our therapeutics by applying our platform to a set of carefully selected scientifically and clinically validated disease specific targets/pathways. From there, our platform can design a single compound to regulate these targets simultaneously, maximizing the treatment potential.
Our prospective miRNA therapeutics can be delivered to relevant cell types via existing FDA approved RNAi delivery technologies such as lipid nanoparticles or chemical modifications.
